Tag: PALISADE
Study: More Than 80% of Patients Could Tolerate 2000mg of Peanuts...
Safety and efficacy increased over time with treatment.
New Two-Year PALFORZIA™ Data Show On-going Safety and Efficacy and Continued...
After 2 Years of Daily Treatment, More Than 80% of Patients Were Successfully Desensitized to 2000 mg Peanut Protein or Equivalent of About 14 Peanut Kernels.
Aimmune Therapeutics Presents New AR101 Data Including Demonstrated Reduction in Accidental...
AR101-Treated Patients Who Completed PALISADE Had 95% Increased Probability of Tolerating Any Dose of Peanut Protein in Exit Challenge Compared to Placebo.
Aimmune to Submit FDA Application for Peanut OIT Candidate by End...
If approved, AR101 could be offered as the first FDA approved OIT therapy for peanut allergy.
Results of Phase III Trial of Aimmune's Peanut OIT Therapy
After one year, 3/4 of patients ages 4-17 who received the therapy were able to consume a minimum of 300mg of peanut. Results for adults were less clear.
